Press
RELEASE
Read and download the financial news from NFL Biosciences. To receive our announcements directly in your mailbox subscribe to our mailing list.
October 4, 2021 • 2021 half-year financial and business report
September 21, 2021 • Approval for its patent to be granted in the United States
September 15, 2021 • Phase II/III clinical trial for NFL-101 for smoking cessation approved in France
September 6, 2021 • Analyst coverage launched with Invest Securities
July 20, 2021 - Establishment of a liquidity agreement (in French only)
June 30, 2021 • Success of the IPO on Euronext Growth Paris
June 16, 2021 • NFL Biosciences launches its initial public offering on Euronext Growth Paris (in French only)
June 2, 2021 • French smoking cessation innovation approved for Phase II clinical trial (in French only)